Anti-TRAIL R2/TNFRSF10B, Rabbit-Poly

• 商品コード：NB100-56618SS
• メーカー：NOV
• 包装：0.025mg
• 価格： ¥41,000
• 在庫：無(未発注)

マイリストに追加 マイリストに追加済

• No.： 1
• 文献情報：
  Prabhu VV et al. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Res. 2015 Apr;75(7):1423-32
  Prabhu VV et al
  2015/01/01
  
• 備考：
  Species: Human, Applications: FLOW
• 参照：
  

• No.： 2
• 文献情報：
  Basile JR et al. The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J.
  Basile JR et al
  2001/01/01
  
• 備考：
  Species: Human, Applications: WB
• 参照：
  

• No.： 3
• 文献情報：
  Xu J et al. The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling. Cell Cycle 2014;13(23):3750-8
  Xu J et al
  2014/01/01
  
• 備考：
  Species: Human, Applications: WB
• 参照：
  

• No.： 4
• 文献情報：
  Xu J et al. Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 2013 Nov;288(46):33263-71
  Xu J et al
  2013/01/01
  
• 備考：
  Species: Human, Applications: WB
• 参照：
  

• No.： 5
• 文献情報：
  Jane EP et al. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol. Cancer Ther. 2011 Jan;10(1):198-208
  Jane EP et al
  2011/01/01
  
• 備考：
  Applications: WB
• 参照：
  

• No.： 6
• 文献情報：
  Georgakis GV et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
  Georgakis GV et al
  2005/01/01
  
• 備考：
  Applications: ICC/IF
• 参照：
  

• No.： 7
• 文献情報：
  Younes M et al. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur. J. Cancer 2006 Mar;42(4):542-7
  Younes M et al
  2006/01/01
  
• 備考：
  Applications: WB, IHC-P, Flow-CS
• 参照：
  

• No.： 8
• 文献情報：
  Abdelrahim M et al. 3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006 Apr;27(4):717-28
  Abdelrahim M et al
  2006/01/01
  
• 備考：
  Applications: WB
• 参照：
  

• No.： 9
• 文献情報：
  Wang S et al. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin. Cancer Res. 2010 May;16(9):2591-604
  Wang S et al
  2010/01/01
  
• 備考：
  Species: Human, Applications: IHC-P
• 参照：
  

• No.： 10
• 文献情報：
  Allen JE et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol. Cancer Ther. 2012 Oct;11(10):2087-95
  Allen JE et al
  2012/01/01
  
• 備考：
  Applications: Flow-CS
• 参照：
  

• No.： 11
• 文献情報：
  Zou W et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 2004 Oct;
  Zou W et al
  2004/01/01
  
• 備考：
  Applications:
• 参照：
  

• No.： 12
• 文献情報：
  Koyama S. Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis. J. Gastroenterol. Hepatol. 2003 Jul;
  Koyama S
  2003/01/01
  
• 備考：
  Applications: Flow-CS
• 参照：
  

• No.： 13
• 文献情報：
  Xu J et al. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res. 2006 Oct;66(20):10092-9
  Xu J et al
  2006/01/01
  
• 備考：
  Applications:
• 参照：
  

• No.： 14
• 文献情報：
  Xu J et al. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 2008 Aug;68(16):6718-26
  Xu J et al
  2008/01/01
  
• 備考：
  Species: Human, Applications: WB
• 参照：
  

• No.： 15
• 文献情報：
  Zhang X et al. Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Invest. Ophthalmol. Vis. Sci. 2011 Aug;52(9):6279-85
  Zhang X et al
  2011/01/01
  
• 備考：
  Species: Mouse, Applications: IHC, ICC/IF
• 参照：
  

• No.： 16
• 文献情報：
  Fan QL et al. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother. Pharmacol. 2005 Feb;55(2):189-96
  Fan QL et al
  2005/01/01
  
• 備考：
  Applications:
• 参照：
  

• No.： 17
• 文献情報：
  Song JH et al. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J. Neurosci. 2006 Mar;26(12):3299-308
  Song JH et al
  2006/01/01
  
• 備考：
  Applications:
• 参照：
  

• No.： 18
• 文献情報：
  Burns TF et al. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001 Aug;20(34):4601-12
  Burns TF et al
  2001/01/01
  
• 備考：
  Applications:
• 参照：
  

• No.： 19
• 文献情報：
  Qiu F et al. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy. Sci Rep 2013;3:3565
  Qiu F et al
  2013/01/01
  
• 備考：
  Species: Human, Applications: WB
• 参照：
  

• No.： 20
• 文献情報：
  Kusaba M et al. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J. Hepatol. 2007 Oct;47(4):546-55
  Kusaba M et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 21
• 文献情報：
  Kim K et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 2000 Feb;6(2):335-46
  Kim K et al
  2000/01/01
  
• 備考：
  
• 参照：
  

• No.： 22
• 文献情報：
  Zhang HG et al. Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver. J. Virol. 2002 Jun;76(11):5692-700
  Zhang HG et al
  2002/01/01
  
• 備考：
  
• 参照：